Allogeneic and Matched Unrelated Donor Stem Cell Transplantation for Congenital Immunodeficiencies or Patients With Autoinflammatory/Immunodysregulatory Conditions: Busulfan-Based Conditioning With Campath- 1H or h-ATG, Radiation, and Sirolimus.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Alemtuzumab; Busulfan; Sirolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 11 May 2021 Biomarkers information updated
- 20 Jan 2012 Official Title amended as reported by ClinicalTrials.gov.
- 14 Apr 2011 Planned End Date changed from 1 Aug 2011 to 1 Aug 2015, according to ClinicalTrials.gov.